Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) Clear all
Terminated Phase 2 Interventional Results available

Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)

NCT04668209
View directory record Official record
Conditions
Coronavirus
Interventions
Silmitasertib
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Phoenix, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 17, 2026, 1:59 PM EDT
Available No phase listed Expanded access

Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

NCT07332338
View directory record Official record
Conditions
Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome, Long COVID, Chronic Fatigue, Chronic Fatigue Symptoms, Fatigue Post Viral
Interventions
REGENECYTE®
Biological
Lead sponsor
StemCyte, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
2
States / cities
Miami, Florida • Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 17, 2026, 1:59 PM EDT
Recruiting Phase 1 Interventional

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

NCT05141058
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Coronavirus-specific T cell (CST)
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 17, 2026, 1:59 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

NAC for Attenuation of COVID-19 Symptomatology

NCT05074121
View directory record Official record
Conditions
Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Lower Respiratory Infection, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
Interventions
N-acetylcysteine, Placebo
Drug · Other
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Everett, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 17, 2026, 1:59 PM EDT
Active, not recruiting Not applicable Interventional

A Study of Positive Emotions With Long COVID-19

NCT05676008
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Microdosing of mindfulness
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 17, 2026, 1:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

NCT05585632
View directory record Official record
Conditions
SARS-CoV-2, Influenza, RSV
Interventions
mRNA-1010, mRNA-1345, mRNA-1273.214, mRNA-1045, mRNA-1230
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
14
States / cities
DeLand, Florida • Hollywood, Florida • St. Petersburg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 17, 2026, 1:59 PM EDT
Terminated Phase 2 Interventional Results available

Pegylated Interferon Lambda Treatment for COVID-19

NCT04343976
View directory record Official record
Conditions
COVID-19, COVID
Interventions
Pegylated interferon lambda
Drug
Lead sponsor
Raymond Chung
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 17, 2026, 1:59 PM EDT
Completed Phase 2 Interventional

Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19

NCT06821087
View directory record Official record
Conditions
Long COVID
Interventions
Ketamine only
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 17, 2026, 1:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 IgG Formation in Physicians at ALGH and Their Household Members

NCT04540484
View directory record Official record
Conditions
Covid19, SARS-CoV Infection, Communicable Disease
Interventions
Screening
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 17, 2026, 1:59 PM EDT
Completed Phase 4 Interventional Results available

Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19

NCT04809974
View directory record Official record
Conditions
Covid19, Sequelae of; Infection, Cognitive Symptom
Interventions
Niagen
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 17, 2026, 1:59 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S in Adults (COVID-19)

NCT04436276
View directory record Official record
Conditions
Covid-19 Prevention
Interventions
Ad26.COV2.S, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,085 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
7
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 17, 2026, 1:59 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19)

NCT05087524
View directory record Official record
Conditions
SARS-CoV2 Infection, COVID-19
Interventions
BinaxNOW Ag Card
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
5 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 17, 2026, 1:59 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Conversational Agent Vaccine Promotion RCT

NCT04884750
View directory record Official record
Conditions
Pandemics
Interventions
ECA-ACE Vaccination Promotion Intervention
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 17, 2026, 1:59 PM EDT
Active, not recruiting No phase listed Observational

A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans

NCT04852289
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 17, 2026, 1:59 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

NCT05011513
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332, Ritonavir, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
78
States / cities
Pelham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 17, 2026, 1:59 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection

NCT04858425
View directory record Official record
Conditions
Covid19
Interventions
Niclosamide, Placebo
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • DeLand, Florida • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 17, 2026, 1:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

NCT05158140
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V110, V114, mRNA-1273, Placebo for V110, Placebo for V114
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
42
States / cities
North Hollywood, California • Northridge, California • Paramount, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 17, 2026, 1:59 PM EDT
Completed Phase 2 Interventional Results available

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

NCT04463004
View directory record Official record
Conditions
COVID-19, Sars-CoV2, Pneumonia
Interventions
Mavrilimumab, Placebos
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 17, 2026, 1:59 PM EDT
Completed Not applicable Interventional

Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections

NCT04395911
View directory record Official record
Conditions
AKI, ARDS, COVID
Interventions
SCD
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Lexington, Kentucky • Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 17, 2026, 1:59 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Understanding the Long-term Impact of COVID on Children and Families

NCT05172011
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 25 Years
Enrollment
15,028 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
65
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 17, 2026, 1:59 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

NCT04466098
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
Interventions
Mesenchymal stromal cells, Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Minneapolis, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 17, 2026, 1:59 PM EDT
Completed Phase 2 Interventional Results available

Convalescent Plasma for Patients With COVID-19

NCT04385199
View directory record Official record
Conditions
Coronavirus Infection, Coronavirus, COVID
Interventions
Convalescent plasma
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 17, 2026, 1:59 PM EDT
Completed Phase 1 Interventional Results available

AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics

NCT05281601
View directory record Official record
Conditions
SARS-CoV-2
Interventions
AZD7442
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Long Beach, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 17, 2026, 1:59 PM EDT
Completed Phase 3 Interventional Results available

Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)

NCT04546581
View directory record Official record
Conditions
COVID, COVID-19, SARS-CoV-2, SARS (Severe Acute Respiratory Syndrome)
Interventions
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo, Remdesivir
Biological · Other · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Colorado Springs, Colorado • Lakewood, Colorado • Westminster, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 17, 2026, 1:59 PM EDT